Tumor Necrosis Factor Inhibitor Drug Market

Tumor necrosis factor inhibitor drug helps to stop physiologic response to tumor necrosis factor.

Tumor Necrosis Factor Inhibitor Drug Market contains market size and forecasts of Tumor Necrosis Factor Inhibitor Drug in global, including the following market information:

• Global Tumor Necrosis Factor Inhibitor Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Tumor Necrosis Factor Inhibitor Drug Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Tumor Necrosis Factor Inhibitor Drug companies in 2021 (%)

The global Tumor Necrosis Factor Inhibitor Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Humira Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Tumor Necrosis Factor Inhibitor Drug include AbbVie Inc., Amgen Inc., Johnson & Johnson, UCB, Novartis AG, Pfizer, Inc., Merck & Co., Inc., CASI Pharmaceuticals and EPIRUS Biopharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Tumor Necrosis Factor Inhibitor Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Tumor Necrosis Factor Inhibitor Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Tumor Necrosis Factor Inhibitor Drug Market Segment Percentages, by Type, 2021 (%)

• Humira
• Enbrel
• Remicade
• Simponi
• Cimzia
• Biosimilars

Global Tumor Necrosis Factor Inhibitor Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Tumor Necrosis Factor Inhibitor Drug Market Segment Percentages, by Application, 2021 (%)

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Juvenile Idiopathic Arthritis
• Crohn?s Disease
• Ulcerative Colitis
• Others

Global Tumor Necrosis Factor Inhibitor Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Tumor Necrosis Factor Inhibitor Drug Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Tumor Necrosis Factor Inhibitor Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Tumor Necrosis Factor Inhibitor Drug revenues share in global market, 2021 (%)
• Key companies Tumor Necrosis Factor Inhibitor Drug sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Tumor Necrosis Factor Inhibitor Drug sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson
• UCB
• Novartis AG
• Pfizer, Inc.
• Merck & Co., Inc.
• CASI Pharmaceuticals
• EPIRUS Biopharmaceuticals
• LEO Pharma
• PROBIOMED
• Shanghai Pharmaceuticals Holding Co., Ltd.